Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | METAP2 | P50579 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.45 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28361711 | 0.79 | APEX1 (0.60) | APEX1METAP2KDM4ETDP1MEN1 | |
| SCHEMBL109573 | 0.79 | KDM4E (0.60) | APEX1METAP2KDM4ETDP1MEN1 | |
| Hydrochloric Acid SCHEMBL15054390 | 0.78 | APEX1 (0.58) | APEX1METAP2KDM4ETDP1MEN1 | |
| SCHEMBL1323012 | 0.78 | APEX1 (0.58) | APEX1METAP2KDM4ETDP1MEN1 | |
| Hydrochloric Acid SCHEMBL143713 | 0.78 | APEX1 (0.58) | APEX1METAP2KDM4ETDP1MEN1 | |
| SCHEMBL111313 | 0.75 | ALDH1A1 (0.76) | APEX1METAP2KDM4ETDP1MEN1 | |
| SCHEMBL7544693 | 0.75 | KDM4E (0.59) | APEX1METAP2KDM4ETDP1MEN1 | |
| SCHEMBL6036030 | 0.75 | MEN1 (0.57) | APEX1METAP2KDM4ETDP1MEN1 | |
| SCHEMBL341961 | 0.74 | APEX1 (0.71) | APEX1METAP2KDM4ETDP1MEN1 | |
| SCHEMBL11609447 | 0.74 | FABP4 (0.59) | APEX1KDM4ETDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126979-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9126980-B2 | Compounds for inhibiting the interaction of BCL2 with binding partners | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2015-03-19 | — | — | US | disclosed |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | UCB PHARMA S.A. (BE) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343093-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | APEX1 608/4885METAP2 3962/4885KDM4E 2918/4885 |
| US-20140357633-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | APEX1 608/4885METAP2 3962/4885KDM4E 2918/4885 |
| US-20140357666-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | APEX1 608/4885METAP2 3962/4885KDM4E 2918/4885 |
| US-20140350014-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | APEX1 608/4885METAP2 3962/4885KDM4E 2918/4885 |
| US-20150080428-A1 | COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS | BCL2, BCL2A1, BCL2L1 | APEX1 692/4885METAP2 3789/4885KDM4E 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.